INTRODUCTION
β-thalassemia major (TM) is an inherited disorder of hemoglobin synthesis characterized by ineffective erythropoiesis and compensatory erythroid hyperplasia. 1 Regular blood transfusions are effective in supplying normal erythrocytes and partially suppressing erythroid marrow expansion. [2] [3] [4] Iron overload is the main negative consequence of transfusion therapy and remains a major cause of morbidity and mortality in TM patients. This necessitates life-long iron chelation therapy to avoid/remove the toxicity of iron overload and improve survival. 5 A dynamic regulation between erythropiesis and iron overload in patients with β -thalassemia has been described, where ineffective erythropoiesis leads to increased intestinal iron absorption through the hepatic hormone hepcidin. 6 Moreover, there is mounting evidence from animal studies that treatment of iron overload affects erythropoietic capacity and leads to improvements in hemoglobin level and red cell survival. [7] [8] [9] Similar evidence from clinical studies is limited and is primarily reported in myelodyslastic syndrome patients receiving the oral chelator deferasirox (DFX) and showing hematologic responses or decreased transfusion requirement; although DOI: 10.3324/haematol.2012.076240 some cases of different anemias including thalassemia and using other chelators were also reported.
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We undertook an evaluation of hematopoietic peripheral progenitors (HPP) in patients with TM with the initial aim of assessing if enough HPP could be collected for a possible gene transfer therapy trial with β globin constructs. Because we found a great heterogeneity in the absolute number of HPP between patients, we conducted the current study with the aim of determining whether such variations are attributable to differences in the type of iron chelation therapy the patients are receiving.
DESIGN AND METHODS

Patients
This was a cross-sectional study of 30 out of 112 TM patients attending the Centro della Microcitemia e delle Anemie Congenite at Ospedale Galliera, Genoa, Italy.
Inclusion criteria were regular transfusion therapy to maintain a pre-transfusional hemoglobin level >9.5 g/dL 18 , iron chelation therapy with the same chelator for more than 6 months with a compliance rate evaluated by the treating physician as >80%;
while exclusion criteria were concomitant therapy with hydroxycarbamide or human immunodeficiency virus infection. Twelve age-and sex-frequency matched healthy volunteers were also included as controls for in vitro clonogenic assays and for flow cytometry. The study received local Ethical Committee approval and all participants signed an informed consent prior to recruitment.
For all TM patients, we retrieved data on: splenectomy status, time from splenectomy, serum ferritin level at the time of study and at initiation of the current chelator, type of current chelator, and duration of its use.
Cell Preparation
For all participants, peripheral blood samples were obtained by aspiration into heparinized syringes. In TM patients, samples were collected around midway between two consecutive transfusion sessions. Mononuclear cells (MNC) were isolated by density gradient centrifugation using a lymphocyte separation medium.
After washing, cells were suspended in Iscove's modified Dulbecco's medium (IMDM), supplemented with 10% fetal bovine serum.
Flow Cytometry
Circulating 
Hematopoietic Peripheral Progenitors in Patients and Controls
The median absolute number of circulating CD34+ cells in TM patients was 8. 
Hematopoietic Peripheral Progenitors and Splenectomy Status
Splenectomized patients had lower median absolute number of BFU-E, yet higher CFU-GM and CFU-GEMM than nonsplenectomized patients, although these associations did not reach statistical significance. However, the median absolute number of LTC-IC was significantly higher in splenectomized than nonsplenectomized patients (p=0.043) (Figure 2 ). There were no statistically significant correlations between the time from splenectomy and the absolute number of any of the evaluated HPP.
Hematopoietic Peripheral Progenitors, Iron Overload, and Chelation Therapy
The absolute number of CFU-GM was statistically comparable between patients receiving DFO, DFP, or DFX; although DFP-treated patients showed the lowest values. A similar observation was noted for CFU-GEMM. A significant trend was noted in the absolute number of BFU-E, with DFX-treated patients having higher values than those receiving DFP (p=0.046) or DFO (p=0.008), and DFP-treated patients having higher values than those receiving DFO (0.034). There were no statistically significant differences in the absolute number of LTC-IC between the three chelator groups (Figure 3 ).
There was no significant correlation between the absolute number of HPP and: 1) the duration of use of the current chelator, 2) serum ferritin level at start of the current chelator, 3) serum ferritin level at the time of study, or 4) the variation in serum ferritin level from the beginning of chelation therapy ( Table 2) .
We constructed a multivariate linear regression model with the absolute number of BFU-E as the dependent variables. After adjusting for age, sex, splenectomy status, serum ferritin at the start of chelation therapy, and change in serum ferritin level while on current chelator, the association between higher absolute number of BFU-E and DFX compared with DFO or DFP therapy remained statistically significant (beta: 627.3, 95% CI: 160.7-1093.9, p=0.011).
DISCUSSION
Our study provides evidence that TM patients have higher levels of circulating HPP than normal individuals. Interestingly, the type of chelator used also importantly affects the absolute number of HPP in the circulation. More importantly, we also determined differential effects on the absolute number of HPP by the three available iron chelators. We showed that this variation depends on the type of chelator rather than the extent of iron depletion. It is also relevant that the major variation in HPP in the peripheral blood concerned mainly BFU-E which resulted particularly abundant in patients treated with DFX when compared with patients receiving other chelators. These findings suggest the potential of DFX therapy to induce hematologic responses and decrease transfusion demand. it has been recently shown that DFX, but not other iron chelators, inhibits nuclear factor-kappaB (NF-kB) in myelodysplatic syndromes and in leukemic cell lines; and thus possibly explaining the improved erythropoiesis observed in such patients while on DFX. 31 Whether the same mechanism applies in TM patients warrants further study. In this respect, it may be relevant to emphasize that the determination of BFU-E content is based on the number of "bursts" that one counts in the culture dish after 15 days of culture. Therefore, the higher score in term of BFU-E may have two possible explanations: (a) indeed there is a higher number of BFU-E which are moving from bone marrow to peripheral blood with DFX therapy;
(b) the DFX may render the erythropoiesis more efficient and, as a consequence, more BFU-E may produce a discrete "burst" which, in turn, will lead to a higher score at the end of the culture period.
We also noted a reduction of BFU-E in splenectomized compared with nonsplenectomized TM patients, consistent with a previous observation. 32 It could be hypothesized that spleen may be acting as a reservoir of progenitor cells or as a site where progenitor cell filtration occurs, rather than a source of extramedullary hematopoiesis. 33 However, a more recent study found no association between splenectomy status and the level of CD4+ cells in the peripheral blood of adult thalassemia patients. 21 The main limitation in our work is that we conducted an observational study for the effects of a therapeutic intervention, which means that confounding elements such as indication and patient characteristics cannot be fully ruled out despite statistical adjustment. A residual confounding may persist. Moreover, we were unable to evaluate HPP in a group of thalassemia patients off iron chelation therapy.
Such investigation will help delineate the effects of the disease from those of the iron chelation intervention on HPP levels in the circulation.
In conclusion, our results suggest that the type of chelation therapy in TM patients influences the level of circulating HPP, especially BFU-E. Our observations should be confirmed through larger, randomized trials and should stimulate further research onto the role of DFX therapy in improving erythropoiesis and associated clinical endpoints in patients with TM.
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